MILESTONE PHARMACEUTICALS IN (MIST) Forecast, Price Target & Analyst Ratings

NASDAQ:MIST • CA59935V1076

Current stock price

1.69 USD
-0.01 (-0.59%)
At close:
1.69 USD
0 (0%)
Pre-Market:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MILESTONE PHARMACEUTICALS IN (MIST).

Forecast Snapshot

Consensus Price Target

Price Target
$6.73
+ 298.34% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Mar 20, 2026
Period
Q4 / 2025
EPS Estimate
-$0.16
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
80.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$6.73
Upside
+ 298.34%
From current price of $1.69 to mean target of $6.73, Based on 11 analyst forecasts
Low
$2.02
Median
$8.16
High
$8.40

Price Target Revisions

1 Month
0.00%
3 Months
76.00%

Price Target Summary

11 Wall Street analysts provided a forecast for the next 12 months for MIST. The average price target is 6.73 USD. This implies a price increase of 298.34% is expected in the next year compared to the current price of 1.69.
The average price target has been revised upward by 76% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

MIST Current Analyst RatingMIST Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6

Analyst Ratings History

MIST Historical Analyst RatingsMIST Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
80.00%
MIST was analyzed by 11 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about MIST.
In the previous month the buy percentage consensus was at a similar level.
MIST was analyzed by 11 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-01-06HC Wainwright & Co.Reiterate Buy -> Buy
2025-12-16Wells FargoMaintains Overweight -> Overweight
2025-12-15TD CowenUpgrade Hold -> Buy
2025-12-15HC Wainwright & Co.Maintains Buy -> Buy
2025-09-11Wells FargoInitiate Overweight
2025-04-01HC Wainwright & Co.Maintains Buy -> Buy
2025-03-28HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-17HC Wainwright & Co.Reiterate Buy -> Buy
2025-02-28HC Wainwright & Co.Reiterate Buy -> Buy
2025-01-27HC Wainwright & Co.Reiterate Buy -> Buy
2024-10-14HC Wainwright & Co.Reiterate Buy -> Buy
2024-08-22Rodman & RenshawInitiate Buy
2024-08-22HC Wainwright & Co.Reiterate Buy -> Buy
2024-07-01HC Wainwright & Co.Reiterate Buy -> Buy
2024-05-30HC Wainwright & Co.Reiterate Buy -> Buy
2024-05-16HC Wainwright & Co.Reiterate Buy -> Buy
2024-03-22HC Wainwright & Co.Reiterate Buy -> Buy
2024-03-05Piper SandlerMaintains Overweight -> Overweight
2024-02-26HC Wainwright & Co.Reiterate Buy -> Buy
2023-12-27TD CowenMaintains Outperform -> Outperform
2023-08-14HC Wainwright & Co.Reiterate Buy -> Buy
2023-06-20JefferiesDowngrade Buy -> Hold
2023-05-23HC Wainwright & Co.Reiterate Buy -> Buy
2023-05-15HC Wainwright & Co.Reiterate Buy -> Buy
2023-04-12OppenheimerMaintains Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date
Mar 20, 2026
Period
Q4 / 2025
EPS Estimate
-$0.16
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
17.99%
Number of Analysts
7

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
4.76%

Next Earnings Summary

MIST is expected to report earnings on 3/20/2026. The consensus EPS estimate for the next earnings is -0.16 USD and the consensus revenue estimate is 0 USD.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
MIST revenue by date.MIST revenue by date.
15M5M
-66.67%		1M
-80.00%
-100.00%		27.107M30.447M
12.32%		107.61M
253.43%		279M
159.27%		370.67M
32.86%		295.6M
-20.25%		337.82M
14.28%		367.3M
8.73%
EBITDA
YoY % growth
MIST ebitda by date.MIST ebitda by date.
-42.98M
15.08%		-59.55M
-38.55%		-61.006M
-2.45%		-38.76M
31.16%		-20.4M
51.43%		-61.914M
-203.50%		-58.854M
4.94%		-13.158M
77.64%		65.586M
598.45%		158.3M
141.36%		N/AN/AN/A
EBIT
YoY % growth
MIST ebit by date.MIST ebit by date.
-43.07M
15.07%		-59.64M
-38.47%		-61.098M
-2.44%		-41.018M
31.09%		-61.38M
-45.79%		-62.938M
-2.54%		-94.401M
-49.99%		-62.866M
33.41%		76.84M
222.23%		154.56M
101.15%		109.45M
-29.19%		147.9M
35.13%		187.68M
26.90%
Operating Margin
MIST operating margin by date.MIST operating margin by date.
-287.13%-1,192.80%-6,109.80%N/AN/A-232.18%-310.05%-58.42%27.54%41.70%37.03%43.78%51.10%
EPS
YoY % growth
MIST eps by date.MIST eps by date.
-1.02
41.04%		-1.37
-34.31%		-1.39
-1.46%		-0.63
50.43%		-0.73
-6.00%		-0.52
28.21%		-0.82
-57.10%		-0.60
27.55%		0.54
190.60%		1.14
111.32%		0.98
-14.29%		N/AN/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q4 / 25 Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.16
17.99%		0.19
161.69%		-0.22
-9.65%		-0.22
-87.00%		-0.22
-37.50%		-0.19
-201.33%		-0.18
16.28%		-0.18
18.18%		-0.17
22.73%
Revenue
Q2Q % growth		76.582M1.241M2.568M4.386M4.59M
-94.01%		5.1M
310.96%		5.61M
118.46%		6.12M
39.53%
EBITDA
Q2Q % growth		-21.318M
-74.12%		N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-15.586M
-26.22%		18.962M
192.39%		-22.105M
-76.40%		-22.464M
-89.90%		-21.88M
-40.38%		-19.482M
-202.74%		-19.278M
12.79%		-18.972M
15.54%		-18.564M
15.15%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

MIST Yearly Revenue VS EstimatesMIST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
MIST Yearly EPS VS EstimatesMIST Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1 -2 -3

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
-6.13%
EPS Next 5 Year
22.73%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
-12.79%
EBIT Next 5 Year
29.19%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

MILESTONE PHARMACEUTICALS IN / MIST Forecast FAQ

What is the average price target for MILESTONE PHARMACEUTICALS IN (MIST) stock?

11 analysts have analysed MIST and the average price target is 6.73 USD. This implies a price increase of 298.34% is expected in the next year compared to the current price of 1.69.

Can you provide the upcoming earnings date for MILESTONE PHARMACEUTICALS IN?

MILESTONE PHARMACEUTICALS IN (MIST) will report earnings on 2026-03-20, before the market open.

What are the consensus estimates for MIST stock next earnings?

The consensus EPS estimate for the next earnings of MILESTONE PHARMACEUTICALS IN (MIST) is -0.16 USD and the consensus revenue estimate is 0 USD.

Can you provide the analyst count for MILESTONE PHARMACEUTICALS IN stock?

The number of analysts covering MILESTONE PHARMACEUTICALS IN (MIST) is 11.